Business Wire

CEGID

3.6.2021 08:02:05 CEST | Business Wire | Press release

Share
KKR to make Investment in Cegid valuing the Company at €5.5 Billion

Cegid, a leading provider of business management software solutions, and KKR, a leading global investment firm and one of the world’s leading technology and software investors, today announced that KKR will acquire a minority stake in the company at an Enterprise Value of €5.5 Billion. Silver Lake, a global leader in technology investing, will remain the majority shareholder and is committed to continuing to support Cegid’s growth strategy driven by the management team over the several coming years, in partnership with KKR and existing shareholder AltaOne.

Founded in 1983 and headquartered in Lyon, France, Cegid is a leading provider of enterprise software, offering functional (HCM, Finance and Tax), as well as vertical (CPA & SMB, Retail) cloud-based solutions. Cegid has been a SaaS pioneer and is today a European leader in providing cloud-based solutions since inception in 2004. Cegid provides cloud-based solutions to over 350,000 companies and 4.5 million users across the globe. Since Silver Lake’s investment in 2016, the company has extended its market leadership and experienced strong double-digit revenue and earnings growth, driven by focusing on SaaS solutions, as well as robust investments in next-generation cloud products and value-enhancing acquisitions.

Pascal Houillon, CEO of Cegid, said: “We are very proud of what we have built over the years and the high growth we have achieved. We have meaningfully expanded Cegid’s market reach geographically, as well as broadened our product portfolio and the range of customers we serve today, who have been trusting the Cegid teams and our expanded capabilities. We have developed a strong suite of best-in-class cloud products across all of our six business segments, continuously improved customer service and extended our offering through strategic acquisitions to grow existing markets and enter new verticals. We are looking forward to continuing the close and trusted partnership we have formed with Silver Lake, who have supported us on our value creation path with their deep software expertise and will carry on doing so over the years. As we continue to invest in world-class, useful and innovative cloud-based solutions, we are thrilled to welcome KKR as a new shareholder. We are convinced that their experience and support will be highly valuable in the next stage of the Cegid journey alongside our existing investors at the service of our clients’ business goals today and in the future.”

Christian Lucas, Co-Head of Silver Lake EMEA, said: “Cegid has developed an outstanding software platform that provides a full range of best-in-class and mission-critical business management solutions across a wide variety of verticals and customer groups. Its focus on cloud-based solutions, as well as its customer-centric approach, have propelled a strong growth trajectory. It continues to be a great pleasure to partner with Pascal and the entire Cegid management team since our investment. We look forward to supporting Cegid’s continued development as a European cloud champion as the majority shareholder for years to come and are delighted to build on the newly formed partnership with KKR as a basis for our continued engagement. We are convinced that KKR will be able to contribute a wealth of relevant expertise on this path and welcome them as new investors.”

Jean-Pierre Saad, Head of EMEA Technology at KKR, and Jérôme Nommé, Head of France at KKR, said: “We are excited to be part of Cegid’s journey going forward. We have followed the company for many years and have been impressed by the growth that Pascal and his team have achieved, transforming Cegid into a pan-European software leader. Today’s investment reflects our continued strategic focus on investing in leading European software businesses and on backing French tech champions in their growth journeys. We look forward to partnering with Cegid’s management team, Silver Lake and AltaOne to accelerate further Cegid’s next phase of growth.”

KKR is making its investment through its Core Investments strategy, which represents capital targeting longer-term opportunities.

The transaction is anticipated to close by the end of the third quarter subject to customary conditions and regulatory approvals. Further terms of the investment are not being disclosed at this time.

About Cegid

Cegid is a leading provider of cloud business management solutions for finance (ERP, cash management, tax), payroll & talent management, CPAs and retail professionals. With a proven track record in cloud management solutions, Cegid provides long term commitment to customers and helps digitalize businesses, from small to large businesses, from private to public sector. Cegid combines a proactive and pragmatic approach of business with expertise in new technologies and a unique understanding of regulations. In a rapidly changing world, Cegid makes more possible and helps customers unleash their potential thanks to innovative and purposeful business solutions.

Cegid has 3,000 employees and markets its solutions in 75 countries. In 2020, Cegid recorded a turnover of €498 million. Pascal Houillon has been the CEO since March 2017.

For more information: www.cegid.com ; http://jobs.cegid.com/

Follow Cegid on social media

https://www.facebook.com/CegidGroup/
https://twitter.com/CegidGroup
https://www.youtube.com/user/CegidOfficiel
https://www.linkedin.com/company/cegid

About Silver Lake

Silver Lake is a global technology investment firm, with more than $83 billion in combined assets under management and committed capital and a team of professionals based in North America, Europe, and Asia. Silver Lake's portfolio companies collectively generate more than $196 billion of revenue annually and employ more than 448,000 people globally. For more information about Silver Lake and its portfolio, please visit www.silverlake.com .

About KKR

KKR is a leading global investment firm that offers alternative asset management and capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of The Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at kkr.com and on Twitter @KKR_Co.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye